877-202-0205     support@chemchart.com     @chemchart
        
Sign In    Register
   Reset Filters

Nervous system drug, Monoamine oxidase inhibitors

Categories

Drugs acting on the nervous system (12)
Psychoactive drugs (12)
Antidepressants (5)
Psychoanaleptics (5)
Psychopharmacology (5)
Monoamine releasing agents (4)
Phenethylamines (4)
Substituted amphetamines (4)
Antiparkinsonian agents (3)
Norepinephrine-dopamine releasing agents (3)
Pharmaceuticals (3)
Anxiolytics (2)
Cyclic compounds (2)
Monoamine reuptake inhibitors (2)
Reversible inhibitors of MAO-A (2)
Acids (1)
Alcohols (1)
Amines (1)
Aromatic compounds (1)
Bases (chemistry) (1)
Benzodioxins (1)
Carboxylic acids (1)
Ethers (1)
Halides (1)
Neurotoxins (1)
Nootropics (1)
Norepinephrine reuptake inhibitors (1)
Organic acids (1)
Organobromides (1)
Organohalides (1)
Piperidines (1)
Serotonin releasing agents (1)
Serotonin reuptake inhibitors (1)
Serotonin-norepinephrine-dopamine releasing agents (1)
Six-membered rings (1)

Suppliers

Sigma Aldrich (4)
Matrix Scientific (1)
Toronto Research Chemicals (1)

Deprenyl (14611-51-9, 2323-36-6)  
Selegiline, also known as L-deprenyl, is a substituted phenethylamine. At normal clinical doses, it is a selective irreversible MAO-B inhibitor. In larger doses it loses its specificity and also inhibits MAO-A.
Marindinin (587-63-3)  
Dihydrokavain is one of the six major kavalactones found in the kava plant. It appears to contribute significantly to the anxiolytic effects of kava, based on a study in chicks.
Bifemelane (62232-46-6, 90293-01-9)  
MCI-2016  ·  2-(4-methylaminobutoxy)diphenylmethane  ·  Celeport
Bifemelane (INN) (Alnert, Celeport), or bifemelane hydrochloride (JAN), also known as 4-(O-benzylphenoxy)-N-methylbutylamine, is an antidepressant and cerebral activator that is widely used in the treatment of cerebral infarction patients with depressive symptoms in Japan, and in the treatment of senile dementia as well. It also appears to be useful in the treatment of glaucoma. Bifemelane acts as a monoamine oxidase inhibitor (MAOI) of both isoenzymes, with competitive (reversible) inhibition of MAO-A (Ki = 4.20 μM) (making it a reversible inhibitor of monoamine oxidase A (RIMA)) and non-competitive (irreversible) inhibition of MAO-B (Ki = 46.0 μM), and also acts (weakly) as a norepinephrine reuptake inhibitor.
BEFLOXATONE (134564-82-2)  
Befloxatone (MD-370,503) is a reversible inhibitor of monoamine oxidase A.
Brofaromine (63638-91-5)  
Brofaromine (proposed brand name Consonar) is a reversible inhibitor of monoamine oxidase A (RIMA) discovered by Ciba-Geigy. The compound was primarily researched in the treatment of depression and anxiety but its development was dropped before it was brought to market. Brofaromine also acts as a serotonin reuptake inhibitor, and its dual pharmacologic effects offered promise in the treatment of a wide spectrum of depressed patients while producing less severe anticholinergic side effects in comparison with older standard drugs like the tricyclic antidepressants.
D-Deprenyl (4528-51-2)  
D-Deprenyl, also known as or dextro-N-propargyl-N-methylamphetamine, is an MAO-B inhibitor that metabolizes into D-amphetamine and D-methamphetamine and is therefore also a norepinephrine-dopamine releasing agent. It is the opposite enantiomer of L-deprenyl (selegiline). L-Deprenyl, also an MAO-B inhibitor, metabolizes to L-amphetamine and L-methamphetamine, which are both norepinephrine releasing agents.
Benmoxin (7654-03-7)  
benmoxine
Benmoxin (trade names Neuralex, Nerusil), also known as mebamoxine, is an irreversible and nonselective monoamine oxidase inhibitor (MAOI) of the hydrazine class. It was synthesized in 1967 and was subsequently used as an antidepressant in Europe, but is now no longer marketed.
(Cyclohexylmethyl)hydrazine (3788-16-7)  
Cimemoxin (INN), or cyclohexylmethylhydrazine, is a hydrazine monoamine oxidase inhibitor (MAOI) antidepressant which was never marketed.
Domoxin (61-74-5)  
Domoxin (INN) is a hydrazine derivative monoamine oxidase inhibitor (MAOI) antidepressant which was never marketed.
3,4-Dichloroamphetamine (4806-87-5)  
3,4-Dichloroamphetamine (DCA), is an amphetamine derived drug invented by Eli Lilly in the 1960s, which has a number of pharmacological actions. It acts as a highly potent and selective serotonin releasing agent (SSRA) and binds to the serotonin transporter with high affinity, but also acts as a selective serotonergic neurotoxin in a similar manner to the related para-chloroamphetamine, though with slightly lower potency. It is also a monoamine oxidase inhibitor (MAOI), as well as a very potent inhibitor of the enzyme phenylethanolamine N-methyl transferase which normally functions to transform noradrenaline into adrenaline in the body.
Carbenzide (3240-20-8)  
Carbenzide (INN), also known as carbazic acid, is a hydrazine derivative monoamine oxidase inhibitor (MAOI) antidepressant which was never marketed.
Related searches
Nervous system drug
Monoamine oxidase inhibitors